Plasma From Convalescent Donors Beneficial for COVID-19-Induced ARDS
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 30, 2023 -- For patients with COVID-19-induced acute respiratory distress syndrome (ARDS), administration of plasma from convalescent donors with a neutralizing antibody titer of at least 1:160 within five days after initiation of invasive mechanical ventilation reduces mortality at 28 days, according to a study published online Oct. 26 in the New England Journal of Medicine. The study was published to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 21 to 25 in Milan.
Benoît Misset, M.D., from the University Hospital of Liège in Belgium, and colleagues randomly assigned adults with COVID-19-induced ARDS who had been receiving invasive mechanical ventilation for less than five days to receive convalescent plasma with a neutralizing antibody titer of at least 1:320 or standard care alone (237 and 238 patients, respectively). Due to a shortage of convalescent plasma, 17.7 percent of patients in the convalescent-plasma group received a neutralizing antibody titer of 1:160.
Glucocorticoids were administered to 98.1 percent of the patients. The researchers found that mortality was 35.4 and 45.0 percent in the convalescent-plasma and standard-care groups, respectively, at day 28. This effect was mainly seen in patients who underwent randomization 48 hours or less after initiation of invasive mechanical ventilation in a prespecified analysis. There was no substantial difference noted between the groups in serious adverse events.
"We believe our trial has a good potential for generalizability to most patients with COVID-19-induced ARDS because almost 50 percent of such patients were included in the centers during their participation in the trial," the authors write.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Following Drop After COVID-19 Onset, Inappropriate Antibiotic Prescribing Is Up
WEDNESDAY, May 1, 2024 -- There was an initial decrease in inappropriate antibiotic prescriptions following onset of COVID-19, followed by an increase, according to a study...
Long-Term Smell, but Not Taste, Deficits Seen After COVID-19
WEDNESDAY, May 1, 2024 -- Olfactory dysfunction, especially for smell, is more common in individuals with prior COVID-19 versus individuals with no history of infection, with...
SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk
TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.